Navigation Links
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
Date:2/17/2011

while another group (12 people) had an additional hour of conventional occupational therapy only. (Three patients did not complete the trial.)

Comparisons between the functional abilities of the two groups showed that stimulation therapy "significantly reduced disability and improved voluntary grasping beyond the effects of considerable conventional upper extremity therapy in individuals with tetraplegia," the authors write.

Dr. Popovic notes that patients who received only occupational therapy saw a "gentle improvement" in their grasping ability, but the level of improvement achieved with FES therapy was at least three times greater using the Spinal Cord Independence Measure, which evaluates degree of disability in patients with spinal cord injury.

A biomedical engineer, Dr. Popovic holds the Toronto Rehabilitation Institute Chair in Spinal Cord Injury Research. He is also a professor in the Institute of Biomaterials and Biomedical Engineering at the University of Toronto.

Based on their findings, the study's authors recommend that stimulation therapy should be part of the therapeutic process for people with incomplete spinal cord injuries whose hand function is impaired. Dr. Popovic's team is working to make this a reality. They have almost completed a prototype of their stimulator, but need financial support to take it forward. Dr. Popovic thinks the device could be available to hospitals within a year of being funded.

"FES (stimulation therapy) has the potential to have a significant and positive impact on the lives of individuals living with the devastating results of spinal cord injury," says Dr. Anthony Burns, Medical Director of Toronto Rehab's spinal cord rehabilitation program. Calling the trial "groundbreaking," Dr. Burns says he will work with Dr. Popovic "to make this intervention available to our patients, and to answer important questions such as the duration of the effect."

One limitation of the
'/>"/>

Contact: Carolyn Lovas
lovas.carolyn@torontorehab.on.ca
416-320-0147
Toronto Rehabilitation Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. First-of-its-kind map details the height of the globes forests
2. American Sociological Association launches first-of-its-kind teaching tool
3. Designing new molecular tools to study the life and death of a cancer cell
4. Scripps Research study sheds light on RNA on/off switches
5. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
6. Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study
7. NSF funds study of landscape restoration effects on Pennsylvania stream
8. VTT to study one of worlds oldest beers
9. Brandeis study shows economic impact of dengue virus in Americas
10. Field study of smoggy inversions to end
11. Road may disrupt migration, ruin Serengeti, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First-of-its-kind study shows benefits of electrical stimulation therapy for people paralyzed by spinal cord injury
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Inc. and AmberGen, Inc. announced today that ... whereby AmberGen will provide its proprietary photocleavable ... SomaLogic,s SOMAscanTM technology platform. The ... high-throughput proteomic quantitation platform is achieving sufficient ...
... of rainbow trout -- one in Alaska, the other in ... implications for fisheries conservation and management, an eight-member research team ... of development that has allowed these different salmomid subspecies to ... researchers, in a paper put online ahead of publication in ...
... a plant pathologist. His most recent research project revolved ... analyzed a special class of genes that encode cell ... these enzymes when attacking a plant. But while investigating ... came in different sizes in different individuals. To ...
Cached Biology News:Genetic buzzer-beater genes may save fish 2Genetic buzzer-beater genes may save fish 3Shedding light on the 'dark matter' of the genome 2Shedding light on the 'dark matter' of the genome 3Shedding light on the 'dark matter' of the genome 4
(Date:12/19/2014)... 18, 2014  Decision Resources Group finds that the ... will grow moderately through 2023 as the aging population, ... of dental biomaterials all spur procedure volumes. Growth will ... China and India ... within reach for a larger proportion of the population. ...
(Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... 3 Trials on Track for Initiation Later This Year ... at 8:30 a.m. Eastern Time -, SAN DIEGO, ... announced today that an independent Echocardiographic,Data Safety Monitoring Board ... ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and,Lorcaserin ...
... 11 GeneGo, Inc. and the Cystic,Fibrosis Foundation ... for the integration and analysis of cystic fibrosis ... and,algorithms for understanding the complex interconnected pathways that ... this collaboration will better help us to understand ...
... in October At U.S. Psychiatric Congress, PARSIPPANY, ... that it has acquired the unique Bipolar Disorder,treatment, ... EQUETRO(R) is a treatment for the acute manic ... condition where patients experience,extended periods of exaggerated highs ...
Cached Biology Technology:Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review 6GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis 2GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis 3Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R) 2
8 different frozen tissues are mounted on positively charged glass slides...
... The MEGAscript RNAi Kit ... of large mass amounts of ... in non-mammalian systems. The MEGAscript ... Ambions patented high-yield transcription technol-ogy ...
...
... VSO LF (Low Flow) offers the same benefits ... for applications where control is critical or flow ... valve automates the flow of gas in proportion ... DC current or pulse width modulation; closed loop ...
Biology Products: